AstraZeneca and Oxford University: Confirms immune response in elderly, phase 3 vaccine trial results in weeks
|AstraZeneca and Oxford University jointly developed COVID-19 vaccine-induced immune response in older adults in their phase 2 trial, the British drug makers confirmed Thursday.
Additional details
“AstraZeneca phase 2 study does not assess efficacy against COVID-19. “
“Results of phase 3 AstraZeneca vaccine trial expected in weeks.”
Market implications
Amid positive vaccine news coming in from Pfizer and Moderna, with over 90% efficacy in the clinical trials, the latest development from AstraZeneca is quite encouraging.
But it does little to impress to markets, which are unnerved by the growth of covid cases and new shutdowns across the globe.
S&P 500 futures stall its recovery, trading at 3,570, up 0.11% so far.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.